Committee on Oversight and Government Reform Witness Disclosure Requirement — "Truth in Testimony"

Pursuant to House Rule XI, clause 2(g)(5) and Committee Rule 16(a), non-governmental witnesses are required to provide the Committee with the information requested below in advance of testifying before the Committee. You may attach additional sheets if you need more space.

1. I lease list ally elicity you are t	estifying on behalf of and l	oriefly describe your i	elationship with these er	ntities.				
Name of Entity	Your relationship with the entity							
Koch Intitute for Integrative Concer Research of MIT	2							
Research of MIT	Director							
2. Places list any federal grants	or contracts (including subs	rranta or aubaantraata	way on the entity on enti	tion listed above bove	raceived since			
2. Please list any federal grants of January 1, 2015, that are related to			you or the entity of enti	ties fisted above have	received since			
Recipient of the grant or	Grant or Contract				Ι			
contact (you or entity above)	Name	Agency	Program	Source	Amount			
2. Please list any payments or co	ontracts (including subconti	eacts) you or the entity	or entities listed above	have received since Is	nuary 1 2015 fro			
a foreign government, that are re			of chities fisted above	nave received since se	inuary 1, 2015 IIC			
Recipient of the grant or	Grant or Contract		D	G	T			
contact (you or entity above)	Name	Agency	Program	Source	Amount			
					1			

Signature

Date: March 77,2017

Page l of Z

Federal Funds: Applicable to Cancer Research

Recipient of Funds: Tyler E. Jacks, Ph.D.

From January 1, 2015 to Current

Recipient	Grant/ Project Title	Agency	Program	Source	Total Costs	Annual Total	Funding Period
	Myofibroblasts in GI Cancers: A						
	novel GEMM to study tumor-CAF			NCI - Subaward from			- 4. 4 4 4
Jacks, Tyler E	interactions	NIH		Columbia University	31,200.00	31,200.00	8/1/14-7/31/15
	(PQB3) Investigating innate						
	immunosurveillance of oncogene-						
	induced danger signals	NIH	R01		1,300,726.00	325,181.00	5/16/14-4/30/18
	(PQB6)Elucidating metastasis by						
	real-time monitoring and tagging						
Jacks, Tyler E	of CTCs in GEMMs	NIH	R01		1,215,026.00	300,670.00	9/1/14-8/31/18
	Adaptive Resistance Mechanisms						
· · · · · , , , ·	in Glioblastoma Tumors	NIH	P30		746,692.00		9/13/16-4/30/17
Jacks, Tyler E	Year 45S2 - BWH Subaward Child	NIH	P30		250,000.00	,	
Jacks, Tyler E	Year 45S2 - Mayo Clinic Child	NIH	P30		221,091.00	221,091.00	
	Extracellular matrix-targeted						
	immunocytokines for pancreatic						
Jacks, Tyler E	cancer treatment	NIH	P30		395,141.00	395,141.00	9/13/16-4/30/17
Jacks, Tyler E	Administration	NIH	P30		20,285,940.00	4,057,188.00	5/1/10-4/30/15
	Cancer Center Support (Core)						
Jacks, Tyler E	Grant ? (Parent)	NIH	P30		17,863,220.00	3,572,644.00	5/1/15-4/30/20
Sharp, Phillip A,	Characterization of Pathways						
1 11 1	Controlling Cancer at the Level of						
1 ' '	Gene Regulation	NIH	P01		2,064,498.00	419,406.00	6/1/12-5/31/17
Tammola Tuomas	Investigating Wnt and Lgr5						
	signaling as regulators of lung						
E, Mentor PI	cancer heterogeneity	NIH	к99		245,746.00	122,873.00	9/9/14-9/15/17
	TMEN - Project 2: T. Jacks	NIH	U54		1,070,978.00		9/23/11-7/31/16
Jacks, Tyler E	SYSTEMATIC IDENTIFICATION OF	INIT	054		1,070,978.00	210,996.00	9/23/11-//31/10
	ONCOGENIC KRAS SYNTHETIC			NCI - Subaward from The			
India Talan 5		NIH			1 122 200 00	200,000,00	0/25/45 0/24/40
Jacks, Tyler E	LETHAL INTERACTIONS	NIH		Broad Institute	1,123,200.00	280,800.00	9/25/15-8/31/19
	Project 3: Models for genetic			100 6 1 16			
	assessment of tumor maitenance	l		NCI - Subaward from	4 200 27- 22	222 24 / 22	7/2/42 42/24/5
Jacks, Tyler E	genes in PDAC	NIH		UTX-MD Anderson	1,360,375.00	322,314.00	7/3/12-12/31/15
	Developing Novel Therapeutic						
	Approaches in small cell lung						
	cancinoma using genetically						
	engineered mouse models and						
Jacks, Tyler E	s, Tyler E human circulating tumor cells. U.S. A		and Material	Command	822,675.00	274,225.00	9/15/13-9/14/16

Foreign Governmental Funds: Applicable to Cancer Research

Recipient of Funds: Tyler E. Jacks, Ph.D.

From January 1, 2015 to Current

					Funding	Funding
Recipient	Recipient				Period Start	Period End
Last Name	First Name	Grant/ Project Title	Agency	Annual Total	Date	Date
		Understanding the mechanism of metastic dissemination in small lung				
Jacks	Tyler	cancer	Swiss National Science Foundation	\$ 71,850	2015-01-01	2017-06-30
Jacks	Tyler	Investigating tumor progression and metastasis in small cell lung cancer"	Agency for Science Technology & Research	\$ 60,084	2012-09-01	2017-08-31